Experiences with

Saphnelo

Going to try the Saphnelo infusions.... has anyone had experience with this? Similar to Benlysta but not as much research out yet... thanks.

From these, 23 were on standard Saphnelo, 29 on intensified Saphnelo, and 23 on the placebo.

The results showed that, compared with 2022, the use of both Benlysta and Saphnelo increased by 32% in both regions.

My USA insurance says I would need to find and infusion center that offers Saphnelo, pay, and submit reimbursment later.

AstraZeneca is the developer of Saphnelo, an approved therapy for moderate to severe systemic lupus erythematosus, the most common form of lupus. [i]https://lupusnewstoday.com/news/lfa-lupus-self-management-care-program-gets-free-mobile-app/?

Saphnelo (anifrolumab-fnia), an approved treatment for adults with moderate to severe SLE, works by blocking the receptor to which IFN-1 normally bind. Most studies supporting the association between IFN-1 activity and the features of SLE have focused on treated patients.

The report noted that Saphnelo and Gazyva are two of the investigational therapies for lupus nephritis being viewed with particular excitement by clinicians. https://lupusnewstoday.com/news/2-new-meds-completely-changed-lupus-nephritis-treatment-report/?

These include, for example, Saphnelo (anifrolumab-fnia), a therapy developed by AstraZeneca that was approved to treat patients with moderate to severe SLE in the U.S. last year.

The trial is recruiting participants at a site in Germany.Two disease-specific treatments have been approved to date for lupus: AstraZeneca’s Saphnelo (anifrolumab) and GlaxoSmithKline’s Benlysta (belimumab).

Did anyone try the new drug Saphnelo? It is from Astra Zeneca and the molecule is called anifrolumab. If yes, any results? Good or bad?

“Having another potential treatment option like Saphnelo is extremely exciting.” “The approval of Saphnelo is the culmination of years of clinical development,” said Susan M.

In July 2021, the FDA approved Saphnelo (anifrolumab-fnia) as the second targeted therapy to treat adults with systemic lupus. It is designed to target and reduce the impact of the Type 1 Interferon Receptor, which may be important in lupus.